• Explore /
  • Poster
  • / A randomized, multicenter, open-label, phase 2 study of TRK-950 in combination with ramucirumab and paclitaxel as second-line therapy in patients with Caprin-1 positive gastric or gastroesophageal junction (G/GEJ) adenocarcinoma.

A randomized, multicenter, open-label, phase 2 study of TRK-950 in combination with ramucirumab and paclitaxel as second-line therapy in patients with Caprin-1 positive gastric or gastroesophageal junction (G/GEJ) adenocarcinoma.

Abstract Poster

Authors

Ronan Kelly

Ronan Joseph Kelly

Charles A. Sammons Cancer Center, Baylor University Medical Center at Dallas, Dallas, TX

Ronan Joseph Kelly , Dani Ran Castillo , Kensei Yamaguchi , Ken Kato , Toshihiro Kudo , Zev A. Wainberg , Sun Young Rha , Jeeyun Lee , Min-Hee Ryu , Fumiyoshi Okano , Kohei Shitara

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2024 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Track

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Sub Track

Esophageal or Gastric Cancer - Advanced/Metastatic Disease

Clinical Trial Registration Number

NCT06038578

Citation

J Clin Oncol 42, 2024 (suppl 16; abstr TPS4181)

DOI

10.1200/JCO.2024.42.16_suppl.TPS4181

Abstract #

TPS4181

Poster Bd #

160b

Abstract Disclosures

Similar Posters

First Author: Ronan Joseph Kelly

First Author: Sun Young Rha

First Author: Sun Young Rha

First Author: Jiao Hu